Pictet Asset Management Holding SA Acquires 46,931 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Pictet Asset Management Holding SA increased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,941,271 shares of the company’s stock after purchasing an additional 46,931 shares during the period. Pictet Asset Management Holding SA owned approximately 2.25% of IDEAYA Biosciences worth $49,891,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after buying an additional 443,640 shares during the period. Barclays PLC boosted its stake in shares of IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock valued at $5,739,000 after purchasing an additional 118,438 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of IDEAYA Biosciences by 12.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock valued at $21,830,000 after purchasing an additional 78,518 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of IDEAYA Biosciences in the 3rd quarter worth about $246,000. Finally, RA Capital Management L.P. acquired a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth about $42,681,000. Institutional investors own 98.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on IDYA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Stephens restated an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock opened at $17.05 on Friday. The firm has a fifty day moving average of $20.80 and a two-hundred day moving average of $25.84. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -5.17 and a beta of 0.76. IDEAYA Biosciences, Inc. has a 52 week low of $16.88 and a 52 week high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.